Startups
Biopharma and medtech deal activity continued to slow in Q3
Our biopharma and medtech reports offer overviews of upfront cash, IPOs, potential acquisitions and other trends we may see throughout the remainder of 2022.
Biopharma R&D partnerships, medtech and overall dealmaking continued to decline across the subsectors in the third quarter of 2022.
J.P. Morgan's biopharma therapeutics and medtech licensing reports examine activity in each sector to provide insights on industry trends. The reports, powered by DealForma, highlight:
- Deal values in biopharma licensing partnerships
- Trends in deal values for medical devices, diagnostics, digital health therapies and research tools
- Venture investment amounts in therapeutic and platform companies
- The advanced therapies that are seeing healthy investment and dealmaking
- IPO and M&A activity in each sector
Download the full reports to understand these life sciences dealmaking trends and see what they may mean for the months ahead.
Technology and Disruptive Commerce
Healthcare
IPO
Markets and Economy
Life Sciences
Startups
Credit and Financing
